264 related articles for article (PubMed ID: 34292776)
21. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
22. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
24. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.
Vlaming M; Ausems MGEM; Schijven G; van Oort IM; Kets CM; Komdeur FL; van der Kolk LE; Oldenburg RA; Sijmons RH; Kiemeney LALM; Bleiker EMA
Fam Cancer; 2024 Jun; 23(2):165-175. PubMed ID: 38722431
[TBL] [Abstract][Full Text] [Related]
25. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
26. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
28. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
30. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of germline variants in inflammatory breast cancer.
Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
33. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
[TBL] [Abstract][Full Text] [Related]
34. Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.
Cecener G; Guney Eskiler G; Egeli U; Tunca B; Alemdar A; Gokgoz S; Tasdelen I
Mol Biol Rep; 2016 Nov; 43(11):1273-1284. PubMed ID: 27573125
[TBL] [Abstract][Full Text] [Related]
35. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
37. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
Behl S; Hamel N; de Ladurantaye M; Lepage S; Lapointe R; Mes-Masson AM; Foulkes WD
Sci Rep; 2020 Apr; 10(1):6491. PubMed ID: 32300229
[TBL] [Abstract][Full Text] [Related]
38. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
[TBL] [Abstract][Full Text] [Related]
39. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
40. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
